Validation of the ISGLS classification of bile leakage after pancreatic surgery: A rare but severe complication.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 01 05 2022
revised: 17 06 2022
accepted: 20 06 2022
pubmed: 17 7 2022
medline: 15 12 2022
entrez: 16 7 2022
Statut: ppublish

Résumé

Hepaticoenterostomy is an important step of reconstruction during hepatopancreatobiliary (HPB) surgery with a subsequent bile leakage rate of up to 5%. The International Study Group of Liver Surgery (ISGLS) proposed a severity grading system for defining bile leakage after HPB surgery, which has not been validated after pancreatic surgery in a large patient cohort. The present study aimed to validate the ISGLS definition for bile leakage in pancreatic surgery and to investigate the postoperative outcomes of bile leakage after pancreatic resections. Data from the prospectively maintained database for pancreas surgery were extracted for any type of pancreatectomy with hepaticoenterostomy between 2006 and 2019. The severity of bile leakage was graded according to the ISGLS definition. The influence of our standardized hepaticoenterostomy technique and of the complexity of the surgical procedure on the rate of clinically relevant bile leakages (B and C) were assessed in three different timeframes. Bile leakage was detected in 152 of 5,300 patients (2.9%). Clinically relevant bile leakages included seventy patients with grade B and eighty-two patients with grade C bile leakages (46.1% and 53.9%, respectively). During the study period, the overall rate of bile leakage showed to be stable (from 3.5% to 2.4%). Patients with grade C bile leakage had a higher rate of postoperative wound infection (P < 0.001) and longer ICU stays and hospital stays compared to patients with grade B bile leakage (P = 0.03 and P < 0.001 respectively). These parameters were significantly higher in patients with late grade C bile leakage but were similar between patients with grade B bile leakage and early grade C bile leakage (<5th day POD). In the whole patients' cohort, the 90-day mortality rate was 3.2% (174/5,300), with a rate of 25% in patients with bile leakage (38/152). The ISGLS classification is a valid method for classifying postoperative bile leak after pancreas surgery. Standardization of our hepaticoenterostomy technique resulted in a stable rate of bile leakage. Although rare, bile leakage following pancreas surgery is a severe complication that has a major impact on patient outcomes and contributes significantly to morbidity and mortality, even in the absence of POPF.

Identifiants

pubmed: 35842371
pii: S0748-7983(22)00535-2
doi: 10.1016/j.ejso.2022.06.030
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2440-2447

Informations de copyright

Copyright © 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Auteurs

Arianeb Mehrabi (A)

Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, 69120, Germany; Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, 69120, Heidelberg, Germany; European Pancreas Center, Heidelberg University Hospital, 69120, Heidelberg, Germany. Electronic address: arianeb.mehrabi@med.uni-heidelberg.de.

Sepehr Abbasi Dezfouli (S)

Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, 69120, Germany.

Fabian Schlösser (F)

Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, 69120, Germany.

Ali Ramouz (A)

Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, 69120, Germany.

Elias Khajeh (E)

Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, 69120, Germany.

Sadeq Ali-Hasan-Al-Saegh (S)

Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, 69120, Germany.

Martin Loos (M)

Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, 69120, Germany; European Pancreas Center, Heidelberg University Hospital, 69120, Heidelberg, Germany.

Oliver Strobel (O)

Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, 69120, Germany; European Pancreas Center, Heidelberg University Hospital, 69120, Heidelberg, Germany.

Beat Müller-Stich (B)

Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, 69120, Germany; Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, 69120, Heidelberg, Germany.

Christoph Berchtold (C)

Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, 69120, Germany.

Markus Mieth (M)

Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, 69120, Germany; Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, 69120, Heidelberg, Germany.

Miriam Klauss (M)

Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, 69120, Heidelberg, Germany; Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, 69120, Heidelberg, Germany.

De-Hua Chang (DH)

Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, 69120, Heidelberg, Germany; Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, 69120, Heidelberg, Germany.

Mark O Wielpütz (MO)

Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, 69120, Heidelberg, Germany; Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, 69120, Heidelberg, Germany.

Markus W Büchler (MW)

Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, 69120, Germany; Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, 69120, Heidelberg, Germany; European Pancreas Center, Heidelberg University Hospital, 69120, Heidelberg, Germany.

Thilo Hackert (T)

Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, 69120, Germany; Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, 69120, Heidelberg, Germany; European Pancreas Center, Heidelberg University Hospital, 69120, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH